← Leaderboards
Joseph N Contessa
Yale University
$6,133,778
Attributed
$6,518,009
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2011–24$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,518,009 · 6
By mechanism
R01$5,835,134 · 4
S10$600,000 · 1
R03$82,875 · 1
Top collaborators
- Evan D Morris3 shared
Most similar at Yale University
Same institution · by research overlap
- Peter M Glazer$37,467,142
- Richard A Flavell$31,785,615
- Evan D Morris$16,421,063
- Phong Trang$159,486
- Zhe Chen$913,596
Others in their field
Top investigators on “Epidermal Growth Factor Receptor”
- Norman Wolmark · Nsabp Foundation, Inc.$27,726,714
- Walter John Curran · Thomas Jefferson University$26,641,549
- Robert J Coffey · Vanderbilt University$24,542,527
- Pasi A Janne · Stanford University$23,416,433
- John H Sampson · Duke University$21,673,210
- Jennifer R Grandis · University Of Pittsburgh At Pittsburgh$19,623,343
Research focus
Epidermal Growth Factor ReceptorSmall MoleculeBaseTumorPathway InteractionsGlycosylationClinical TrialsProteinsCellsAnimal ModelLinkSiteHigh Throughput ScreeningEndoplasmic ReticulumDesignReceptor Protein-Tyrosine KinasesNormal Tissue MorphologySmall Molecule InhibitorRadiation TherapyIn VitroIn VivoAsparagineInhibitor/AntagonistPolysaccharides
Grant awards (18)
OST Inhibition in NSCLC$463,580
R01 · FY2024 · CA · contact PI
OST Inhibition in NSCLC$478,219
R01 · FY2023 · CA · contact PI
"Small Animal Radiation Research Platform (SARRP) for Yale University".$600,000
S10 · FY2022 · OD · contact PI
OST Inhibition in NSCLC$478,219
R01 · FY2022 · CA · contact PI
OST Inhibition in NSCLC$487,978
R01 · FY2021 · CA · contact PI
OST Inhibition in NSCLC$487,978
R01 · FY2020 · CA · contact PI
Regulation of N-linked glycosylation in Mammalian Cells$323,647
R01 · FY2019 · GM · contact PI
Targeting N-linked Glycosylation to Enhance Radiation Therapy$397,474
R01 · FY2018 · CA · contact PI
Regulation of N-linked glycosylation in Mammalian Cells$335,007
R01 · FY2018 · GM · contact PI
Targeting N-linked Glycosylation to Enhance Radiation Therapy$399,961
R01 · FY2017 · CA · contact PI
Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer$255,891
R01 · FY2017 · CA
Targeting N-linked Glycosylation to Enhance Radiation Therapy$408,361
R01 · FY2016 · CA · contact PI
Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer$257,699
R01 · FY2016 · CA
Targeting N-linked Glycosylation to Enhance Radiation Therapy$408,773
R01 · FY2015 · CA · contact PI
Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer$254,873
R01 · FY2015 · CA
Targeting N-linked Glycosylation to Enhance Radiation Therapy$397,474
R01 · FY2014 · CA · contact PI
A bioluminescent screen for inhibitors of N-linked glycosylation$41,500
R03 · FY2012 · DA · contact PI
A bioluminescent screen for inhibitors of N-linked glycosylation$41,375
R03 · FY2011 · DA · contact PI